NCT04283240 (YGGDRASIL) is a EARLY_PHASE1 clinical trial of Sildenafil in Pulmonary Embolism, sponsored by University of Aarhus.

Who is sponsoring NCT04283240?

NCT04283240 is sponsored by University of Aarhus.

What drugs are being tested in NCT04283240?

Interventions in NCT04283240: Sildenafil, Placebo.

What condition does NCT04283240 study?

NCT04283240 studies Pulmonary Embolism.

Is NCT04283240 still recruiting?

NCT04283240 is currently completed. Last updated 25 February 2020.

Last reviewed 2020-02-25 · How we verify

NCT04283240: YGGDRASIL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sildenafil in Acute Pulmonary Embolism

Completed EARLY_PHASE1 Last updated 25 February 2020

What this trial tests

EARLY_PHASE1 trial testing Sildenafil in Pulmonary Embolism in 20 participants. Completed in 10 September 2018.

Timeline

1 March 2015

Primary endpoint
10 September 2017

10 September 2018

Quick facts

Lead sponsor	University of Aarhus
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	20
Start date	1 March 2015
Primary completion	10 September 2017
Estimated completion	10 September 2018
Sites	1 location across Denmark

Drugs / interventions tested

Sildenafil (sildenafil) — full drug profile →
Placebo

Conditions studied

Pulmonary Embolism — all drugs for Pulmonary Embolism →

Sponsor

University of Aarhus

Who can join

Adults 80 to 80, any sex, with Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate if acute pulmonary vasodilation by sildenafil improves right ventricular function in patients with acute intermediate-high risk pulmonary embolism (PE).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives.
ElHady AK, El-Gamil DS, Abdel-Halim M, Abadi AH. · · 2023 · cited 39× · PMID 37765073 · DOI 10.3390/ph16091266
Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial.
Andersen A, Waziri F, Schultz JG, Holmboe S, et al · · 2021 · cited 12× · PMID 33639897 · DOI 10.1186/s12890-021-01440-7
Pulmonary Artery Pulsatility Index in Acute and Chronic Pulmonary Embolism.
Lyhne MD, Yuriditsky E, Zochios V, Dragsbaek SJ, et al · · 2025 · cited 1× · PMID 40005479 · DOI 10.3390/medicina61020363

Verify or expand the search:

Other trials of Sildenafil

Trials testing the same drug.

NCT07039760 — Asciminib With or Without Sildenafil for Brain Tumors · EARLY_PHASE1 · not yet recruiting
NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment · Phase 2, PHASE3 · not yet recruiting
NCT06954597 — Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis · Phase 2 · recruiting
NCT06778330 — The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonar · NA · completed
NCT06875258 — PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II) · Phase 4 · recruiting

Other recruiting trials for Pulmonary Embolism

Currently open trials in the same condition.

NCT07381712 — High-Flow Nasal Cannula Versus Non-Invasive Ventilation for Acute Respiratory Failure in Pulmonary Embolism. · NA · active not recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT07003646 — Reperfusion Treatment in Acute Pulmonary Embolism · recruiting
NCT06600542 — Inari VISION Registry · recruiting
NCT06622876 — Incidental Discovery of Pulmonary Emboli Via CT Scan: Impact of Detections on Patient Care and Resulting Complications · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04283240 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 25 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04283240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing